


Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captions "Version with Marking to Show Changes Made."

Entry of this amendment is respectfully requested.

Respectfully submitted,



Kirk Baumister

Attorney for Applicants

Registration No. 33,833

GLAXOSMITHKLINE

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone: (610) 270-5096

Fax: (610) 270-5073

n:\kb\ptodocs\p50438d2\pmam

"Version with Marking to Show Changes Made."

In the claims:

Claim 1 has been amended as follows:

1. (Amended) A method for inhibiting thrombosis in an animal comprising administering an effective dose of an anti-coagulation factor IX/IXa monoclonal antibody [having self-limiting neutralizing activity].

6. (Amended) The method of [claim 5] claims 1 or 2 wherein the anti-Factor IX monoclonal antibody has the identifying characteristics of SB 249413, SB 249415, SB 249416, SB 2249417, SB 257731 or SB 257732.

7. (Amended) The method of [claim 5] claims 1 or 2 wherein the anti-Factor IX monoclonal antibody has the identifying characteristics of SB 249417.

Claims 3-5, 8, 9, and 11-38 were canceled.

New claims 39-43 were added.